The Genomic Medicine program, one of the three that make up the Precision Medicine Infrastructure associated with Science and Technology (IMPaCT), will have 7.25 million euros and its coordination falls on the director of the Genomic Medicine group of CiMUS from the University of Santiago de Compostela, Dr. Ángel Carracedo. The program will create a new generation national sequencing network to apply in rare diseases, cancer and pharmacogenetics of biomarkers of response to cancer and psychiatric treatments.
Dr. Ángel Carracedo directs the Genomic Medicine group of the CiMUS of the University of Santiago de Compostela
According to Dr. Carracedo, this project “It marks the present and future path of the development of personalized precision medicine in Spain”. In addition, he adds that he will have “A key importance” for the National Health System (SNS) since genomic medicine “It represents a revolution in healthcare by allowing diagnoses, identifying the best treatments and designing prevention strategies”.
The program will have a network of five reference centers for genomic analysis and a
group of clinical experts. Thus, a total of 45 groups from 38 centers (25 hospitals and 13 from research centers or universities) with representation from all the Autonomous Communities will participate.
Dr. Carracedo: “The Genomic Medicine program marks the present and future path of the development of personalized precision medicine in Spain”
In addition to the Genomic Medicine program coordinated by Dr. Carracedo, IMPaCT, which is part of the Strategic Action in Health 2017-2020 of the ISCIII, will also develop the Predictive Medicine and Data Science programs, coordinated by Dr. Marina Pollán , in the Ciber of Epidemiology and Public Health (Ciberesp), and by Alfonso Valencia from the Barcelona Supercomputer Center-CNS.
The objective of the IMPaCT Program on Genomic Medicine is to create a robust collaborative structure for the implementation of genomic medicine in coordination with the National Health System. Thus, the aim is for patients from all territories to have equal access to the genomic tests they need, while obtaining genomic data that can be used in research.
It will create a national sequencing network to apply in rare diseases, cancer and pharmacogenetics of biomarkers of response to cancer treatments and psychiatric diseases
The network of genomic analysis centers and the group of clinical experts will offer highly complex genomic sequencing services. It will also facilitate the interpretation of the results and the preparation of a clinical report for the entire NHS. You will start with three application examples. On the one hand, the diagnosis of rare diseases. On the other, the somatic mutation in cancer. Third, application of pharmacogenetics in cancer and psychiatric diseases.
In addition, the CiMUS (Center for Research in Molecular Medicine and Chronic Diseases) highlights that the Genomic Medicine project will be coordinated with international initiatives such as the European project 1+ Million Genomes, the International Research Consortium on Rare Diseases (IRDiRC) and the Consortium Cancer Genome International (ICGC).